The FDA has approved DCCR (Diazoxide Choline Controlled-Release) for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS)!
This approval is a huge leap forward in improving the health and quality of life for those with PWS. Anish Bhatnagar, M.D., Chief Executive Officer of Soleno states that this “is a significant milestone for Soleno and, most importantly, for the PWS community who have had no options to treat the most disruptive aspect of this disease.”
This decision now paves the way for other countries to seek approval for DCCR, expanding access to this crucial treatment worldwide.
A big thank you to everyone who supported and advocated for this treatment, especially those who participated in the DCCR Clinical Trials. Today, the PWS Community has shown that they can, and are, making a real difference!
